Trial ID: | L7056 |
Source ID: | NCT04032197
|
Associated Drug: |
Semaglutide
|
Title: |
A Research Study of How Semaglutide Works in People With Disease Affecting the Heart and/or Blood Vessels and Type 2 Diabetes
|
Acronym: |
|
Status: |
COMPLETED
|
Study Results: |
NO
|
Results: |
|
Conditions: |
Diabetes Mellitus, Type 2
|
Interventions: |
DRUG: Semaglutide|DRUG: Placebo (semaglutide)
|
Outcome Measures: |
Primary: Change in maximum target-to-background ratio (TBR) for 18F-fluorodeoxyglucose (FDG) in the carotid arteries, Ratio, From baseline (from 41 days before randomisation) to week 26 | Secondary: Change in maximum target-to-background ratio (TBR) for 68Ga-DOTATATE in the carotid arteries, Ratio, From baseline (from 40 days before randomisation) to week 26|Change in total wall volume of the most diseased carotid artery, mm3, From baseline (from 41 days before randomisation) to week 52|Change in lipid rich necrotic core (LRNC) volume of the atherosclerotic plaque in the most diseased carotid artery, mm3, From baseline (from 41 days before randomisation) to week 52|Change in average fibrous cap thickness (FCT) of the atherosclerotic plaque in the most diseased carotid artery, mm, From baseline (from 41 days before randomisation) to week 52
|
Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
Gender: |
ALL
|
Age: |
ADULT, OLDER_ADULT
|
Phases: |
PHASE1
|
Enrollment: |
101
|
Study Type: |
INTERVENTIONAL
|
Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
Start Date: |
2019-08-12
|
Completion Date: |
2023-06-06
|
Results First Posted: |
|
Last Update Posted: |
2024-05-03
|
Locations: |
Clinical Trials Unit / Center for Medical Research, Graz, 8010, Austria|Steno Diabetes Center Copenhagen, Herlev, 2730, Denmark|Karolinska Universitetssjukhuset Solna,FOU Tema Hjärta Kärl, Stockholm, 171 76, Sweden|CTC Clinical Trial Consultants AB, Uppsala, Uppsala, 75237, Sweden
|
URL: |
https://clinicaltrials.gov/show/NCT04032197
|